Figure 2From: Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial Frequency distribution of exacerbations. Data are after 48 weeks of intermittent therapy in (a) the per-protocol end-of-treatment (PP EOT) population and (b) the intent-to-treat (ITT) population.Back to article page